Republican Rep. Nicole Malliotakis of New York has formally requested that the U.S. Department of Justice (DOJ) take immediate action to shut down two federally funded Overdose Prevention Centers (OPCs) in Manhattan. In a letter sent to Attorney General Todd Blanche on Tuesday, Malliotakis urged the DOJ to enforce federal law against the facilities, which provide supervised drug consumption services, including the use of illicit substances like heroin.
The two centers—located in East Harlem and Washington Heights—have been operating under the nonprofit OnPoint NYC, which previously received federal funding. Malliotakis argues that the sites violate Title 21 of the U.S. Code Section 856, which prohibits maintaining a location for the purpose of using controlled substances. She contends that the facilities attract criminal activity and signal drug dealers to potential clients.
A DOJ spokesperson confirmed receipt of the letter and stated that the department is reviewing it. The letter follows recent scrutiny of OnPoint NYC after reports emerged of a former employee allegedly selling fentanyl near the facilities.
Background and Context
The controversy centers on the role of Overdose Prevention Centers (OPCs), which are designed to reduce fatal overdoses by providing supervised drug consumption spaces. Proponents argue that such sites save lives by preventing fatal overdoses and connecting users to addiction treatment services. Critics, including Malliotakis, contend that the facilities enable drug use and violate federal law.
The Biden administration previously provided funding to support harm reduction initiatives, including OPCs, as part of its broader public health strategy. However, the legality of these sites has been a subject of ongoing debate, with federal law enforcement agencies historically opposing their operation.
Political and Legal Implications
Malliotakis’ request to the DOJ reflects broader Republican opposition to harm reduction policies, particularly those tied to federal funding. The letter signals a potential escalation in federal enforcement against OPCs, which have operated in a legal gray area despite state and local approval.
The DOJ’s response will determine whether the facilities face immediate shutdown or continued operation under legal challenge. The outcome could set a precedent for other cities considering similar harm reduction programs.
Recent Developments
In addition to Malliotakis’ letter, reports have emerged regarding alleged misconduct by an employee of OnPoint NYC. A former staff member was accused of selling fentanyl near one of the facilities, raising further concerns about oversight and safety at the sites.
The DOJ’s review of the letter and any subsequent actions will be closely watched by public health advocates, law enforcement, and policymakers as a potential turning point in the debate over harm reduction strategies.